Skip to main content Accessibility help
×
Home

Are the Triptans for Migraine Therapy Worth the Cost?

  • W.J. Becker (a1)

Abstract:

The triptans represent a major advance in migraine therapy but their cost per dose greatly exceeds that of many older treatments. There is evidence that for a significant proportion of migraine patients these new drugs can show a positive cost benefit and also improve quality of life. Cost benefit would be expected to be greatest in patients with more severe migraine attacks.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Are the Triptans for Migraine Therapy Worth the Cost?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Are the Triptans for Migraine Therapy Worth the Cost?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Are the Triptans for Migraine Therapy Worth the Cost?
      Available formats
      ×

Copyright

Corresponding author

Division of Neurology, 12th Floor, Foothills Medical Centre, 1403 - 29th Street NW, Calgary, Alberta T2N 2T9, Canada.

References

Hide All
1. Tfelt-Hansen, P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998 Oct;18(8):532538.
2. Shear, NH, Oh, PI, Arikian, SR, Detsky, AS, Laupacis, A. Pharmacoeconomics: measure of cost and benefit. Ann R Coll Phys Surg Canada 1995;28:239240.
3. Cohen, JA, Beall, DG, Miller, DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996 Mar;28(3):171177.
4. Streator, SE, Shearer, SW. Pharmacoeconomic impact of injectable sumatriptan on migraine associated healthcare costs. Am J Manag Care 1996;2:6776.
5. Legg, RF, Sclar, DA, Nemec, NL, Tarnai, J, Mackowiak, JI. Cost effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997;3:117122.
6. von Korff, M, Stewart, WF, Simon, DJ, Lipton, RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998;50:17411745.
7. Cortelli, P, Cahlof, C Bouchard, J, et al. A multinational investigation of the impact of subcutaneous sumatriptan III. Workplace productivity and non-workplace activity. PharmacoEconomics 1997;11(Suppl.1):3542.
8. Legg, RF, Sclar, DA, Nemec, NL, Tarnai, J, Mackowiak, JI. Cost benefit of sumatriptan to an employer. JOEM 1997;39(7):652657.
9. Fishman, P, Black, L. Indirect costs of migraine in a managed care population. Cephalalgia 1999;19:5057.
10. Michel, P, Dartigues, JF, Duru, G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999;19(5):503510.
11. Davies, GM, Santanello, N, Gerth, W, Lerner, D, Block, GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999;19(5): 497502.
12. Dahlof, C, Bouchard, J, Cortelli, P, et al. A multi-national investigation of the impact of subcutaneous sumatriptan II: health-related quality of life. PharmacoEconomics 1997; 11(Suppl.1):2434.
13. Osterhaus, JT, Gutterman, DL, Plachetka, JR. Healthcare resource and lost labor costs of migraine in the US. PharmacoEconomics 1992;2:6776.
14. Van Roijen, L, Essink-Bot, M-L, Koopmanschap, MA, et al. Societal perspective on the burden of migraine in the Netherlands. PharmacoEconomics 1995;7:170179.
15. Tfelt-Hansen, P, Henry, P, Mulder, LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923926.
16. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177184.
17. Myllylä, VV, Havanka, H, Herrala, L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38:201207.
18. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314322.
19. Reches A. Comparison of the efficacy, safety and tolerability of oral eletriptan and cafergot for the acute treatment of migraine. Cephalalgia 1999;19:355.
20. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19(4):232240.
21. Pryse-Phillips, WEM, Dodick, WD, Edmeads, JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997;156:12731287.
22. Mathews, NT. Drug induced headache. Neurologic Clinics 1990;8:903912.
23. Stewart, WF, Lipton, RB, Whyte, J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999;53(5):988994.
24. Tfelt-Hansen, P, Teal, J, Rodriguez, F, et al on behalf of the Rizatriptan 030 Study Group. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998;38:748755.

Are the Triptans for Migraine Therapy Worth the Cost?

  • W.J. Becker (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed